PYPD PolyPid Ltd.
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1611842 · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year
Growth
TTM revenue YoY—
TTM net income YoY-17.7%
TTM EPS YoY-57.4%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-366.3%
ROA-143.8%
ROIC (approx.)-1,290.9%
Asset turnover—
Leverage & solvency
Liabilities / assets50.8%
Debt / equity0.00x
Current ratio1.97x
Interest coverage-37.72x
Cash quality & payout
Operating cash flow / net income0.82x
Accruals ratio-26.5%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2025Q22025-06-30 | 2024Q22024-06-30 | 2023Q22023-06-30 | 2022Q22022-06-30 | 2021Q22021-06-30 | 2020Q22020-06-30 |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Revenue | — | — | — | — | — | — |
| R&D expense | $6.21M | $4.76M | $3.96M | $8.40M | $7.44M | $4.34M |
| SG&A expense | $2.49M | $1.10M | $1.50M | $2.24M | $2.45M | $2.63M |
| Operating income | -$9.40M | -$6.12M | -$5.82M | -$11.56M | -$10.63M | -$7.27M |
| Pretax income | -$9.92M | -$6.29M | -$5.83M | — | — | — |
| Income tax | $53,000 | $2,000 | $10,000 | — | — | — |
| Net income | -$9.98M | -$6.29M | -$5.84M | -$11.85M | -$10.48M | -$16.99M |
| EPS (basic) | 0.78 | 1.25 | 3.95 | 0.61 | 0.56 | 25.30 |
| EPS (diluted) | 0.78 | 1.25 | 3.95 | 0.61 | 0.56 | 25.30 |
| Weighted avg. shares (diluted) | 12.84M | 5.02M | 1.48M | 19.51M | 18.75M | 755,289 |
| Balance sheet | ||||||
| Cash & equivalents | $17.45M | $3.08M | $3.40M | $11.64M | $8.03M | — |
| Current assets | $29.99M | $9.78M | $15.75M | $25.02M | $49.17M | — |
| PP&E, net | $5.34M | $6.81M | $8.53M | $9.18M | $5.73M | — |
| Total assets | $37.69M | $19.53M | $26.26M | $34.82M | $61.40M | — |
| Current liabilities | $13.15M | $10.29M | $5.45M | $8.70M | $4.32M | — |
| Short-term debt | $6.55M | $5.44M | $2.07M | $2.17M | — | — |
| Long-term debt | — | $3.13M | $8.54M | — | — | — |
| Total debt | — | $8.56M | $10.61M | — | — | — |
| Total liabilities | $17.21M | $17.93M | $17.92M | $15.71M | $4.51M | — |
| Shareholders' equity | $20.48M | $1.60M | $8.35M | $19.11M | $56.88M | $84.48M |
| Net debt | — | $5.49M | $7.21M | — | — | — |
| Shares outstanding | 15.65M | 4.80M | 49.05M | 19.55M | 18.76M | — |
| Cash flow statement | ||||||
| Operating cash flow | — | — | — | — | — | — |
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.